SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively position ahead of its earnings report, fueled by a new strategic partnership with Anthropic and multiple analyst price target hikes. The community is sharply divided between bulls betting on a structural AI memory supercycle and skeptics warning of a bubble, with heavy activity in short-dated options reflecting high anticipation of post-earnings volatility.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility as investors debate the impact of potential government contract losses in Europe against strong enterprise AI adoption and solid fundamentals. The community remains deeply divided, with bears emphasizing valuation concerns and technical breakdowns, while bullish investors highlight the company's long-term role as a foundational layer for defense-oriented AI infrastructure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense downward pressure following its recent IPO as retail investors grapple with extreme volatility, concerns over its massive valuation, and anxiety regarding upcoming insider lock-up expirations. The community remains deeply divided, with some betting on a rapid technical bounce or long-term potential, while vocal skeptics argue the stock is a classic overhyped pump-and-dump scheme headed for significantly lower levels.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following the signing of executive orders to accelerate the federal government's quantum computing efforts, with the company emerging as a central beneficiary of the initiative. Community sentiment is mixed as investors weigh the potential for long-term government-backed growth against concerns over technical performance and broader software sector volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors position for imminent Phase 3 VELA data and upcoming Psoriatic Arthritis trial readouts. The community is actively discussing the company's defensive capital raise and the potential for a high-premium buyout as the firm continues to de-risk its clinical pipeline and strengthen its standalone commercial position.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is drawing significant investor interest as a potential buyout candidate with high short interest, fueling speculation of a possible short squeeze if a take-private deal is announced. Community members are actively debating the company's turnaround potential under new leadership, with many retail investors viewing current price levels as an accumulation opportunity while expressing frustration over perceived market manipulation.

Roundhill ETF Trust - Roundhill Memory ETF

Investors are actively flocking to the Roundhill Memory ETF ($DRAM) as a focused basket play on the ongoing AI infrastructure boom, with community sentiment centered on the critical role of high-bandwidth memory (HBM) and data storage as the primary bottleneck for next-gen AI scaling. The bullish thesis remains rooted in a perceived structural supercycle for memory demand, bolstered by institutional activity, recent strategic partnerships, and expectations that memory producers will experience long-term re-ratings as supply constraints persist.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing significant community attention driven by a new national quantum initiative and potential future collaboration in the space sector. Investors remain highly focused on long-term potential and institutional positioning, with many discussing the stock's role in critical government-backed infrastructure.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh recent oncology trial setbacks against potential long-term value and active speculation regarding future M&A activity. The community remains deeply divided, with many expressing frustration over persistent share price weakness and leadership performance while others advocate for holding through the current volatility for dividend income and potential pipeline catalysts.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing significant momentum and investor interest driven by a major $500 million underwritten public offering, which has sparked heated debate within the community regarding potential dilution versus the company's long-term growth potential. While some investors are actively shorting the stock citing historical dilution concerns, others are holding firm, banking on the company's late-stage clinical progress and the broader positive sentiment surrounding the psychedelic therapeutics sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market tradingread more...

Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection

Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection...

ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs 

Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.

Alvotech (ALVO) Q4 2025 Earnings Transcript

Alvotech (ALVO) Q4 2025 Earnings Transcript...

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (NASDAQ:ALVO) Announces Earnings Results

Alvotech (NASDAQ:ALVO - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $999.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $999.07. Alvotech had a negative return on equity of 11.92% and a net margin of...

Alvotech (NASDAQ:ALVO) Trading 7.1% Higher - Still a Buy?

Alvotech (NASDAQ:ALVO) Trading Up 7.1% - Here's Why...

Alvotech (NASDAQ:ALVO) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Alvotech (NASDAQ:ALVO - Get Free Report) have earned an average recommendation of "Hold" from the six ratings firms that are presently covering the company, Marketbeat reports. Two...

Wall Street Zen Upgrades Alvotech (NASDAQ:ALVO) to Hold

Wall Street Zen raised shares of Alvotech from a "sell" rating to a "hold" rating in a research note on Saturday...

Alvotech (NASDAQ:ALVO) Sees Significant Increase in Short Interest

Alvotech (NASDAQ:ALVO - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 3,000,511 shares, a growth of 22.1% from the March 15th total of 2,457,228 shares. Currently, 1.0% of the shares of the stock are short sold...

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Why Is ALVO Stock Rising Pre-Market Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.65
Prev Close	$3.92
Open	$3.94
Dividend Yield	0.00%
50-Day Moving Average	$3.56
Beta	0.78
Avg. Volume	429,009.32
PE Ratio	-14.85

52-Week High	$9.94
52-Week Low	$2.94
Market Capitalization	$1.31B
EPS (Annual)	$0.0964
Price to Book	-4.59
Revenue Per Employee	$401,589.73

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALVOAlvotech

Latest ALVO News